What The Column Group does

The Column Group (TCG) is a private venture capital firm founded in 2007 by Peter Svennilson in San Francisco, California, dedicated exclusively to building biotechnology companies from inception through exit. TCG operates an "edge-to-edge" investment model deploying capital across four coordinated vehicles: TCG Platform funds (early-stage company formation, making 3-4 investments per year and averaging 10-12 portfolio companies per fund at $50-60 million+ per company), TCG Opportunity funds (later-stage follow-on to concentrate ownership in TCG portfolio companies), TCG Labs-Soleil (a February 2024-launched venture-biotech model integrating a $400 million+ venture fund with an evergreen R&D hub for single-asset biologic therapies), and TCG Crossover/TCGX (a 2021-launched crossover fund for late-stage and public drug-discovery investments that is operationally independent of TCG core).

Over a two-decade history, TCG has started or invested in 55 companies and generated $4.0 billion in returns for partners and portfolio across 18 exits. Notable exits include Carmot Therapeutics (Roche, $3.3B, December 2023), RAPT Therapeutics (GSK, $2.2B, January 2026), Peloton Therapeutics (Merck, up to $2.35B, May 2019), Constellation Pharmaceuticals (MorphoSys, $1.7B, June 2021), Flexus Biosciences (BMS, $1.3B, April 2015), Neurona Therapeutics (UCB, up to $1.15B, April 2026), and Escient Pharmaceuticals (Incyte, $783M, April 2024). Fund family includes TCG IV at $725 million, TCG V at $615 million plus TCG Opportunity III at $615 million ($1.23 billion total), and TCG Labs-Soleil at over $400 million. Revenue is generated through management fees and carried interest on its fund family alongside capital gains from portfolio exits.

TCG's competitive position rests on a deep scientific talent ecosystem — 22 elite academic advisors, 10 National Academy of Sciences members, and one Nobel Prize winner (Jennifer Doudna) serve as iPartners and Science Partners to source, validate, and mentor portfolio ventures. The portfolio spans modalities including small molecules (Atavistik Bio allosteric inhibitors, Nura Bio SARM1 inhibitors, ORIC Pharmaceuticals), engineered cytokines and large molecules (Synthekine, Kallyope), cell therapies (Neurona, Tr1X, A2 Biotherapeutics), gene therapy (Tenaya Therapeutics), and regenerative medicine (Surrozen). TCG also operates the Swanson Fellowship Program (named for Genentech co-founder Robert Swanson) and a centralized portfolio job board as part of its talent and company-formation infrastructure.

Name

The Column Group

Legal name

The Column Group, LLC

Website

https://www.thecolumngroup.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

The Column Group is a private venture capital firm founded in 2007 that builds biotechnology companies from inception through exit. It deploys capital across TCG Platform, Opportunity, Labs-Soleil, and TCGX funds, with $4.0 billion in returns generated across 18 exits and 55 portfolio companies.

Ownership category

akta.pro rank

Product category

Venture Capital (Biotechnology)

NAICS

Portfolio Management and Investment Advice (52394)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industry

Thematic / Sector-Focused Multi-Manager Platforms (FSANAGAH)

Keywords

• Venture capital funds
• Biotech investments
• Life sciences venture
• Company formation
• Venture biotech funding

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Venture capital fund management and carried interest: TCG generates revenue through management fees and carried interest on its venture capital funds — TCG Platform funds (V at $615M early-stage plus Opportunity III at $615M later-stage, total $1.23B), TCG IV ($725M), and TCG Labs-Soleil (over $400M). TCG reports $4.0 billion in returns generated for partners and portfolio across 18 exits.
2. Capital gains from portfolio exits and IPOs: Returns generated through successful portfolio exits (18 to date) and public holdings in companies including Revolution Medicines (RVMD), ORIC Pharmaceuticals (ORIC), Tenaya Therapeutics (TNYA), Arcus Biosciences (RCUS), Nurix (NRIX), Gritstone Bio (GRTS), and RAPT Therapeutics (RAPT). Notable exits include Carmot (Roche, $3.3B), Peloton (Merck, up to $2.35B), Aragon (J&J, up to $1B), Seragon (Genentech, $0.8B), Neurona (UCB, up to $1.15B), Constellation (MorphoSys, $1.7B), Exonics (Vertex, up to $1B), Flexus (BMS, $1.3B), RAPT (GSK, $2.2B), Escient (Incyte, $783M), and Immune Design (Merck, $0.3B).
3. Crossover fund investments (TCGX): TCG Crossover (TCGX), launched in 2021 and operationally independent of TCG, invests in later-stage pre-IPO and public drug discovery companies.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

The Column Group is a private venture capital firm dedicated to founding, funding, and growing biotechnology companies across small molecules, biologics, cell therapy, gene therapy, and regenerative medicine. It deploys capital through a coordinated family of funds — TCG Platform, TCG Opportunity, TCG Labs-Soleil, and TCG Crossover (TCGX) — that together support portfolio companies from inception through exit, supplemented by the Swanson Fellowship Program and a deep scientific advisor network.

Product overview

The Column Group (TCG) is a venture capital firm and life sciences investment platform, not a single software product. Its offering is structured as a platform-plus-modules ecosystem comprising multiple investment vehicles and programs: (1) TCG Platform Funds, the legacy early-stage investment model focused on company formation with 3-4 investments per year; (2) TCG Opportunity Funds, follow-on capital supporting TCG portfolio companies through later stages; (3) TCG Labs-Soleil, a 2024-launched venture-biotech model combining a $400M fund (TCG Labs) with an evergreen R&D hub (Soleil) focused on single-asset biologic therapies; and (4) TCG Crossover (TCGX), the ecosystem's first crossover fund for late-stage pre-IPO and public drug discovery companies (operationally independent). Beyond capital deployment, TCG operates the Swanson Fellowship Program, a one-year biotech leadership fellowship for new company creation, and an iPartners advisory group of leading academic investigators. These vehicles collectively fund and nurture a portfolio of 55+ biotech companies that have generated $4.0 billion in returns and 18 exits, with active companies spanning modalities from small molecules (e.g., Nura Bio, Atavistik Bio, ORIC Pharmaceuticals) and large molecules (e.g., Synthekine cytokines, Kallyope gut-brain axis therapeutics) to cell therapies (e.g., Neurona Therapeutics, Tr1x Bio, A2 Biotherapeutics), gene therapy (e.g., Tenaya Therapeutics), and oligonucleotides (e.g., Judo Bio).

Differentiator

Problem solved

Functional benefit

Brands

• TCG Labs-Soleil: A novel venture-biotech model integrating a dedicated venture fund (TCG Labs, over $400 million) with an evergreen R&D hub (Soleil), focused on single-asset biologic therapies for serious diseases.
• TCG Crossover (TCGX)

Products and services

• TCG Platform Funds Early-stage venture capital funds that partner with scientific founders to build biotech companies from inception through exit, selectively investing in 3-4 highly vetted ideas per year and averaging 10-12 portfolio companies per fund with $50-60M+ typically invested in each company.
• TCG Opportunity Funds Follow-on venture capital funds that build on TCG Platform fund momentum by providing a flexible pool of capital to support TCG's most promising companies through later stages of development and concentrate ownership within the TCG portfolio.
• TCG Labs-Soleil A pioneering venture-biotech model launched in February 2024 that integrates a dedicated venture fund of over $400 million (TCG Labs) with an evergreen R&D hub led by top-tier scientists and drug developers (Soleil), focused on single-asset programs for efficient discovery and development of biologic-based therapies for serious diseases.
• TCG Crossover (TCGX) The first crossover fund debuted under the TCG ecosystem in 2021, dedicated to investing in later-stage pre-IPO and publicly-traded drug discovery companies, with the goal of supporting the translation of cutting-edge science into products that make a meaningful difference for patients.
• Swanson Fellowship Program A one-year fellowship opportunity for aspiring biotech leaders, named in honor of Robert Swanson (co-founder of Genentech), focused on new company creation with hands-on mentorship from the TCG team and its iPartners in a collaborative working environment.

Quantifiable outcome

• $4.0 billion in returns generated for partners and portfolio
• +8 more outcomes

Named customers28 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

19 partnerships are on record, tiered core portfolio company — led $73.8m series b., core portfolio company — co-led $106m seed and series a., major acquirer — acquired neurona therapeutics for up to $1.15b in april 2026., strategic partner — tortugas neuroscience in-licensed clinical-stage cns programs from eisai., strategic partner — tortugas neuroscience in-licensed clinical-stage cns programs from hansoh., major acquirer — acquired rapt therapeutics for $2.2b in january 2026., core portfolio company — co-led series b., core portfolio company — led series a financing., flagship talent and ideation program — named after genentech co-founder robert swanson., major acquirer — acquired escient pharmaceuticals for $783m in april 2024., flagship internal program — $400m+ venture-biotech fund integrated with r&d hub., strategic research collaboration partner with tcg portfolio company atavistik bio., major acquirer — acquired tcg portfolio company carmot therapeutics for $3.3b in december 2023., major acquirer — acquired constellation pharmaceuticals for $1.7b in june 2021., flagship internal program — first crossover fund in tcg ecosystem., major acquirer — acquired exonics therapeutics for up to $1b in june 2019., major acquirer — acquired peloton therapeutics for up to $2.35b in may 2019; also acquired immune design for $0.3b in february 2019., major acquirer — acquired flexus biosciences for $1.3b in april 2015. and major acquirer — acquired aragon pharmaceuticals for up to $1b in august 2013..

• Nura Biocore portfolio company — led $73.8m series b.Strategic or Co-development Partner · 23 June 2026Nura Bio completed a $73.8M Series B led by The Column Group with participation from Samsara BioCapital, Euclidean Capital, and Sanofi Ventures. The funding advances Nura's SARM1 inhibitor pipeline, including a Phase 1b/2a study of NB-4746 for ALS and a first-in-human study of NB-9402, a next-generation covalent allosteric SARM1 inhibitor. Tim Kutzkey, PhD serves on the board; John Josey, PhD is Chairman of Atavistik Bio and involved with Nura Bio board.
• Tortugas Neurosciencecore portfolio company — co-led $106m seed and series a.Strategic or Co-development Partner · 21 April 2026Tortugas Neuroscience launched in Framingham, Massachusetts with $106M in combined seed and Series A financing co-led by Cure Ventures, The Column Group, and AN Venture Partners. Funding supports Phase 2 clinical trials for two lead CNS candidates targeting schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies. Programs were in-licensed from Eisai Co., Ltd. (Japan) and Jiangsu Hansoh Pharmaceutical Group (China). Led by former Sage Therapeutics executives Jeff Jonas (CEO) and Al Robichaud (R&D head).
• UCBmajor acquirer — acquired neurona therapeutics for up to $1.15b in april 2026.Strategic or Co-development Partner · 1 April 2026UCB acquired Neurona Therapeutics (a TCG portfolio company developing cell therapies for neuropsychiatric disorders including epilepsy) in April 2026 for up to $1.15 billion, advancing UCB's leadership in epilepsy through regenerative science.
• Eisai Co., Ltd.strategic partner — tortugas neuroscience in-licensed clinical-stage cns programs from eisai.Strategic or Co-development Partner · 1 April 2026Eisai Co., Ltd. (Japan) licensed clinical-stage CNS drug candidates to Tortugas Neuroscience (TCG portfolio company), targeting schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies.
• Jiangsu Hansoh Pharmaceutical Groupstrategic partner — tortugas neuroscience in-licensed clinical-stage cns programs from hansoh.Strategic or Co-development Partner · 1 April 2026Jiangsu Hansoh Pharmaceutical Group (China) licensed clinical-stage CNS drug candidates to Tortugas Neuroscience (TCG portfolio company).
• GSKmajor acquirer — acquired rapt therapeutics for $2.2b in january 2026.Strategic or Co-development Partner · 1 January 2026GSK acquired RAPT Therapeutics (NASDAQ: RAPT), a TCG portfolio company developing oral therapeutics targeting immune drivers of cancer and inflammation, in January 2026 for $2.2 billion.
• Atavistik Biocore portfolio company — co-led series b.Strategic or Co-development Partner · 18 December 2025Atavistik Bio raised $120M Series B (later extended to $160M total) led by Nextech Invest and The Column Group, with participation from Lux Capital and Regeneron Ventures. The funding advances an oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms (MPNs). HHT program expected to enter the clinic in H1 2026. Also disclosed a research collaboration with Pfizer to accelerate discovery of novel precision allosteric therapeutics.
• Nilo Therapeuticscore portfolio company — led series a financing.Strategic or Co-development Partner · 8 October 2025Nilo Therapeutics launched with a $101M Series A led by The Column Group, DCVC Bio, and Lux Capital, with support from the Gates Foundation and Alexandria Venture Investments. The funding supports labs in New York City, R&D expansion, and preclinical programs targeting neural circuits to restore immune homeostasis in autoimmune and inflammatory diseases. Kim Seth was appointed CEO.
• Swanson Fellowship Program / Robert Swanson legacyflagship talent and ideation program — named after genentech co-founder robert swanson.Others · 1 January 2025The Swanson Fellowship program is a one-year fellowship opportunity for aspiring biotech leaders, focused on new company creation with hands-on mentorship from the TCG team and its iPartners. Named in honor of Robert Swanson, the Co-Founder of Genentech, often considered the father of the biotechnology industry.
• Incytemajor acquirer — acquired escient pharmaceuticals for $783m in april 2024.Strategic or Co-development Partner · 1 April 2024Incyte acquired Escient Pharmaceuticals (TCG portfolio company advancing first-in-class GPCR-targeted drugs) in April 2024 for $783 million.
• TCG Labs-Soleil (internal fund)flagship internal program — $400m+ venture-biotech fund integrated with r&d hub.Strategic or Co-development Partner · 1 February 2024TCG Labs-Soleil, launched in February 2024 with over $400M, represents a pioneering venture-biotech model integrating a dedicated venture fund (TCG Labs) with an evergreen R&D hub (Soleil) led by top-tier scientists. Focused on single-asset programs for efficient discovery and development of biologic-based therapies.
• Pfizerstrategic research collaboration partner with tcg portfolio company atavistik bio.Strategic or Co-development Partner · 1 January 2024Pfizer entered a research collaboration with Atavistik Bio (TCG portfolio company) to accelerate discovery of novel precision allosteric therapeutics for metabolite-protein interactions in metabolic diseases and cancer.
• Rochemajor acquirer — acquired tcg portfolio company carmot therapeutics for $3.3b in december 2023.Strategic or Co-development Partner · 1 December 2023Roche acquired Carmot Therapeutics (a TCG portfolio company using Chemotype Evolution drug discovery) in December 2023 for $3.3 billion. Separately, Genentech/Roche acquired TCG portfolio company Seragon Pharmaceuticals in August 2014 for $0.8 billion.
• MorphoSysmajor acquirer — acquired constellation pharmaceuticals for $1.7b in june 2021.Strategic or Co-development Partner · 1 June 2021MorphoSys acquired Constellation Pharmaceuticals (TCG portfolio company pioneering therapeutics targeting epigenetic regulators) on June 2, 2021 for $1.7 billion.
• TCG Crossover (TCGX)flagship internal program — first crossover fund in tcg ecosystem.Strategic or Co-development Partner · 1 January 2021TCG Crossover (TCGX), launched in 2021, is the first crossover fund debuted under the TCG ecosystem, dedicated to investing in later-stage pre-IPO and public drug discovery companies. Operationally independent of The Column Group (TCG).
• Vertex Pharmaceuticalsmajor acquirer — acquired exonics therapeutics for up to $1b in june 2019.Strategic or Co-development Partner · 1 June 2019Vertex Pharmaceuticals acquired Exonics Therapeutics (TCG portfolio company developing CRISPR/Cas9 gene editing medicines for Duchenne muscular dystrophy) on June 6, 2019 for up to $1 billion.
• Merckmajor acquirer — acquired peloton therapeutics for up to $2.35b in may 2019; also acquired immune design for $0.3b in february 2019.Strategic or Co-development Partner · 1 May 2019Merck acquired TCG portfolio company Peloton Therapeutics (first-in-class small-molecule oncology pipeline) in May 2019 for up to $2.35 billion. Merck also previously acquired TCG portfolio company Immune Design (immunotherapy oncology) in February 2019 for $0.3 billion.
• Bristol-Myers Squibbmajor acquirer — acquired flexus biosciences for $1.3b in april 2015.Strategic or Co-development Partner · 1 April 2015Bristol-Myers Squibb acquired Flexus Biosciences (TCG portfolio company creating cancer therapeutics through immunology insights) in April 2015 for $1.3 billion.
• Johnson & Johnsonmajor acquirer — acquired aragon pharmaceuticals for up to $1b in august 2013.Strategic or Co-development Partner · 1 August 2013Johnson & Johnson acquired TCG portfolio company Aragon Pharmaceuticals (nuclear receptor targeting drugs for hormone resistant cancers) in August 2013 for up to $1 billion.

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Arch Venture Partners: Arch Venture Partners is a leading biotech-focused venture capital firm that co-invests and competes with TCG for early-stage life sciences opportunities, particularly at company formation. Both firms back scientific founders at top universities and have produced multiple pharma exits (Arch: Illumina, Receptos, Vir).
• Flagship Pioneering: Flagship Pioneering is a biotech creation engine that both internally generates companies (like Moderna) and partners with academic founders. Highly comparable to TCG's company-formation-led model and its recent TCG Labs-Soleil venture-biotech hybrid approach.
• Third Rock Ventures: Third Rock Ventures builds biotech companies from academic science with a hands-on operating partner model — directly parallel to TCG's company formation approach. Both firms concentrate on early-stage therapeutic platforms with strong scientific founders.
• Atlas Venture: Atlas Venture is an early-stage biotech venture firm that builds companies from scratch around academic science — a closely comparable model to TCG Platform funds. Both firms back founders across modalities with focused portfolios.
• Versant Ventures: Versant Ventures is a healthcare-focused venture firm with comparable company-creation capabilities (e.g., Inception Sciences). Direct competitor for early-stage biotech deals and a natural co-investor or alternative for biotech founders.
• 5AM Ventures: 5AM Ventures is an early-stage biotech venture firm founded by former TCG-affiliated scientists and focused on company formation. It competes with TCG for academic founders and platform technologies in therapeutics.
• OrbiMed: OrbiMed is one of the largest dedicated healthcare venture firms investing across stages. It is comparable in biotech focus, multi-stage capital deployment, and is a frequent competitor/co-investor of TCG (Leon Chen previously at OrbiMed).

Broad incumbents

• Andreessen Horowitz (a16z Bio): a16z's bio/health fund is a broader, larger tech-oriented investor that has expanded into life sciences. It competes for biotech founders and capital but operates a multi-vertical model with technology as its core, unlike TCG's pure-play biotech focus.
• RA Capital Management: RA Capital is a healthcare-focused crossover and public-market investor (co-invested in Atavistik Bio's Series B extension). Comparable in biotech life-sciences focus but operates a broader crossover/public equity model in addition to private venture.
• Baker Bros. Advisors: Baker Bros. is a long-only biotech-focused investment firm with significant public and private healthcare exposure. Comparable as a high-conviction biotech specialist and competitor for both private rounds and public crossover deals alongside TCGX.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/the-column-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments138 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Column Group